News

Roquette and Bonumose Sign a Global Cooperation Agreement Supporting Tagatose Growth

Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, and Bonumose, a pioneer in enzymatic solutions for rare monosaccharide production, are pleased to announce the signing of a Cooperation Agreement that aims to advance the development of tagatose, a natural-origin sweetener with clinically proven health benefits.

This collaboration combines Roquette’s extensive experience in starch and starch-based sweetener production with Bonumose’s cutting-edge enzymatic technology. By leveraging the strengths of both companies, the agreement aims to enhance the scalability of tagatose, reaffirming Roquette’s commitment to innovative sugar management solutions.

“Roquette is proud to partner with Bonumose to advance tagatose growth,” expresses Anne Hirsch, Head of Sugar Management at Roquette. “We recognize the potential of Bonumose’s innovative enzyme technology, which produces high-purity tagatose. Our large-scale starch sweetener production expertise can significantly enhance processing efficiency post enzymatic conversion. This partnership aligns with our long-term vision of sustainable production and meeting the growing global demand for sweetening solutions.”

Ed Rogers, CEO of Bonumose, adds: “Tagatose closely matches the taste, flavor, and cookability of white sugar while offering health benefits such as reduced calories and an ultra-low glycemic index. We are excited to collaborate with Roquette, given their engineering prowess, and multiple market routes. We are happy to welcome Roquette into our expanding ecosystem of strategic partners supporting tagatose adoption.”

Read more here.

Recent News

07/23/2026

Activation Capital Expands the Bio+Tech Center, Doubling Laboratory Capacity to Strengthen Virginia’s Life Sciences Entrepreneurship and Innovation Ecosystem

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced an expansion of its Bio+Tech Center to support the continued growth of life sciences entrepreneurship across the region. Activation Capital’s Bio+Tech Center is a life sciences incubator located within the Virginia Bio+Technology Research Park. Serving as both a physical and programmatic

07/22/2026

Epidarex Announces Leadership Appointments

With the launch of our latest fund, Epidarex Capital IV, LP, we are pleased to announce several promotions. As we continue to grow and deepen our impact across the US and UK life science ecosystems, recognizing and elevating exceptional talent within our team is a vital part of that journey. These transitions reflect our continued

07/22/2026

Phlow Corp. Appoints Sripathy Venkatraman, Ph.D, As Chief Scientific Officer

Phlow Corp., a U.S.-based advanced pharmaceutical contract development and manufacturing organization (CDMO), dedicated to strengthening the nation’s pharmaceutical supply chain and protecting America’s medicine cabinet, today announced the appointment of Sripathy Venkatraman, Ph.D., MBA, as Chief Scientific Officer. Venkatraman brings more than 25 years of experience in pharmaceutical development, process chemistry, manufacturing, and scientific leadership. He